Intellia Therapeutics downgraded by Bernstein
$NTLA
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Bernstein downgraded Intellia Therapeutics from Outperform to Mkt Perform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/2/2026 | Mkt Perform → Outperform | William Blair | |
| 11/12/2025 | Outperform → Peer Perform | Wolfe Research | |
| 11/11/2025 | $8.00 | Outperform → In-line | Evercore ISI |
| 11/7/2025 | $5.00 | Neutral → Underweight | Analyst |
| 10/28/2025 | $14.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 10/28/2025 | Outperform → Mkt Perform | Bernstein | |
| 10/27/2025 | Outperform → Mkt Perform | William Blair | |
| 10/27/2025 | Buy → Neutral | Guggenheim |
CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that data from the global Phase 3 HAELO clinical trial of lonvo-z (formerly known as NTLA-2002) in hereditary angioedema (HAE) will be presented in a late-breaking oral presentation at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026, taking place June 12-15 in Istanbul, Türkiye. Intellia will also have a poster presentation detailing the burdens experienced by HAE patients living outside the United States. Late-Brea
Presented positive Phase 3 HAELO topline clinical data for lonvo-z in HAE; initiated rolling BLA submission; anticipate U.S. launch in first half of 2027Recently resumed patient screening in MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nex-z in ATTR-CM and ATTRv-PN, respectivelyIncluding proceeds from underwritten public offering in April, existing cash resources expected to fund operations at least into 2028 CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today reported business updates and financial resu
CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that management will be participating in fireside chats at the following upcoming investor conferences: Bank of America Securities Health Care ConferenceDate: Tuesday, May 12, 2026Fireside Chat Time: 3:40 p.m. PTLocation: Las Vegas RBC Capital Markets Global Healthcare ConferenceDate: Wednesday, May 20, 2026Fireside Chat Time: 2:35 p.m. ETLocation: New York Jefferies Global Healthcare ConferenceDate: Wednesday, June 3, 2026Fireside Chat Time: 4:55 p
4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
10-Q - Intellia Therapeutics, Inc. (0001652130) (Filer)
8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)
8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)
4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
William Blair upgraded Intellia Therapeutics from Mkt Perform to Outperform
Wolfe Research downgraded Intellia Therapeutics from Outperform to Peer Perform
Evercore ISI downgraded Intellia Therapeutics from Outperform to In-line and set a new price target of $8.00
World's first Phase 3 readout for an in vivo CRISPR gene editing candidateCompany to host webcast to discuss data at 8:00 a.m. ET on April 27, 2026 CAMBRIDGE, Mass., April 24, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the company will report topline clinical data from its global Phase 3 HAELO clinical trial of lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE) on Monday, April 27, 2026 and will host a webcast at 8:00 a.m. ET to discuss the data. To join the webcast, please visit the Events page of the Inv
Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time treatment of nex-z, supporting the hypothesis that greater TTR reduction may lead to a greater clinical benefit in ATTR amyloidosis Favorable trends consistently observed across multiple markers of cardiac disease progression at month 12 compared to baseline in an ATTR-CM population with a high proportion of advanced heart failure patientsConsistent trend observed to date in ATTRv-PN arm, with stability or improvement of neuropathy as measured by multiple clinical measures of disease progression compared to baselinePersistently deep levels of serum TTR
Deep attack rate reductions achieved in both dose levels tested; a single 50 mg dose resulted in a mean monthly attack rate reduction of 77% and 81% compared to placebo during weeks 1-16 and 5-16, respectivelyEight of 11 patients in the 50 mg arm were completely attack free following a one-time infusion through the latest follow-up; data support NTLA-2002's potential to be a functional cure for hereditary angioedema (HAE)NTLA-2002 demonstrated an encouraging safety and tolerability profileData published in The New England Journal of Medicine and will be presented at the 2024 ACAAI Scientific Meeting Actively screening patients in the global pivotal Phase 3 HAELO study evaluating the 50 mg do
Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met primary and all key secondary endpoints; favorable safety and tolerability data observed Single dose of lonvo-z freed most patients from both attacks and ongoing therapy for six-month efficacy evaluation period, demonstrating its potential to be the first and only one-time HAE treatmentRolling biologics license application (BLA) submission initiated with the U.S. Food and Drug Administration (FDA); anticipate U.S. launch in the first half of 2027, if approvedIntellia to host webcast today at 8:00 a.m. ET CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical comp
HAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half of 2027Process underway to reactivate global sites for MAGNITUDE-2 Phase 3 clinical trial of nex-z in ATTRv-PN; enrollment completion expected in second half of 2026FDA engagement ongoing to resolve clinical hold on MAGNITUDE Phase 3 clinical trial of nex-z in ATTR-CM Ended 2025 with approximately $605 million in cash, cash equivalents and marketable securities; expected to fund operations into the second half of 2027 CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical com
CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company will host a conference call on February 26, 2026, at 8 a.m. ET to discuss its fourth quarter and full-year 2025 financial results and business updates. To join a webcast of the call, please visit this link. To join the teleconference, U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference c
SC 13G/A - Intellia Therapeutics, Inc. (0001652130) (Subject)
SC 13G/A - Intellia Therapeutics, Inc. (0001652130) (Subject)
SC 13G/A - Intellia Therapeutics, Inc. (0001652130) (Subject)